Authors
Latest:
McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid ServicesMcKesson has received approval from the CMS to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.
Latest:
Cancer Treatment Centers of America Grows Medical Oncologist Roster Across HospitalsMedical oncologists Dr. Ajaz Khan, Dr. Ryan Engel, and Dr. Nitika Sharma are the latest board-certified, fellowship-trained physicians who have chosen to practice medicine at Cancer Treatment Centers of America®.
Latest:
Dr. Allaf on Evaluating the PROSPER-RCC Trial Results in RCCMohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.
Latest:
The Future of Reimbursement: How AI Can Revolutionize Oncology PracticesBy retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.
Latest:
Cancer Blood Tests Jumpstart Diagnoses and Targeted TherapyNew research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.
Latest:
McKesson's Patient-Reported Outcomes Measure Will Track Improvements in Health-Related Social NeedsThe use of patient-reported outcome measures—the gold standard in quality measurement—is crucial to building a patient-centered, value-based care system.
Latest:
Dr Albigès on the Predictive and Prognostic Utility of KIM-1 in High-Risk RCCLaurence Albigès, MD, PhD, discusses the potential predictive and prognostic value of circulating KIM-1 in patients with renal cell carcinoma.
Latest:
Dr Rosca on Key Challenges in Genetic Testing for Lung CancerOana Catalina Rosca, MD, discusses key challenges in genetic testing for lung cancer.
Latest:
Future Directions in the Management of Immune ThrombocytopeniaExpert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.
Latest:
Dr Desai on the Benefits and Limitations of Bladder Preservation With Chemoradiation in MIBCNeil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.
Latest:
Practical Advice for Management of Chronic GVHDThe panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.
Latest:
Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should Be LowerSurvivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event than the general public.
Latest:
Addition of Dalpiciclib to Fulvestrant Improves PFS in HR+ Advanced Breast CancerThe addition of dalpiciclib to fulvestrant significantly prolonged progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to data from an interim analysis of the phase 3 DAWNA-1 trial.
Latest:
Multiple Myeloma: Unmet Needs and Future Directions in CareAfter discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
Latest:
Dr Hiltermann on ARTEMIDE-01 Data With Rilvegostomig in Metastatic NSCLCT. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.
Latest:
Dr Thompson on the Necessity of Surgery and Radiation Therapy in Early-Stage Breast CancerAlastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing challenges in determining the optimal treatment strategy for patients with early-stage breast cancer.
Latest:
Dr Hagensee on Strategies For Cervical Cancer PreventionMichael Hagensee, MD, PhD, discusses strategies for cervical cancer prevention and ongoing research investigating barriers to cervical cancer treatment.
Latest:
Dr Childs on Treatment With Olaparib Plus Abiraterone in mCRPCDan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.
Latest:
Dr Armaghani on the Investigation of De-Escalated Treatment Approaches in TNBCAvan Armaghani,cdiscusses the feasibility of de-escalating treatment in triple-negative breast cancer, as well as planned or ongoing research investigating this approach in the neoadjuvant and metastatic settings.
Latest:
Looking Ahead and Key TakeawaysElizabeth O’Donnell, MD, comments on the most significant advancements for frontline therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. She also provides key takeaways from the latest clinical trial data, discussing how she anticipates these findings will impact her day-to-day clinical practice.
Latest:
Future Directions in Biomarker-Based OncologyExperts in oncology discuss future directions in biomarker-driven therapy.
Latest:
Unmet Needs and Future Perspectives in Colorectal CancerThe panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.
Latest:
The Future of Ovarian Cancer TreatmentOncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.
Latest:
Dr Huddart on the FDA Approval of Erdafitinib in FGFR3+ Urothelial CancerRobert Huddart, PhD, discusses the FDA approval of erdafitinib for patients with FGFR3-altered metastatic urothelial carcinoma.
Latest:
The Future of Lower-Risk MDS: Closing Thoughts and Unmet NeedsPanelists discuss how community oncologists can apply key takeaways from this clinical scenario in their practice, emphasizing the importance of collaborating with academic clinicians for optimal patient identification and treatment selection in the evolving landscape of lower-risk MDS management.
Latest:
Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia VeraDr. Pankit Vachhani presents key data from the CYTO-PV and MAJIC-PV studies, evaluating the efficacy of ruxolitinib versus best available therapy in patients with polycythemia vera, focusing on clinical outcomes such as cardiovascular risk reduction, hematocrit management, and long-term molecular responses.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Empowering Community Cancer Care: Importance of Outreach InitiativesIn this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer.
.jpg?fit=crop&auto=format)
